21336183	238	Camidge DR	Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.	Journal of thoracic oncology 	2011	61
22071784	238	McLeer-Florin A	Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study.	Journal of thoracic oncology 	2012	40
22129856	238	Paik JH	Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma.	Lung cancer	2012	34
23344087	238	Kim S	Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.	Journal of thoracic oncology 	2013	38
12198537	673	Rajagopalan H	Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status.	Nature	2002	276
18832519	673	Ogino S	CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.	Gut	2009	259
19276360	673	Hoeflich KP	Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.	Cancer research	2009	50
20635392	673	Tie J	Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.	International journal of cancer	2011	39
21285991	673	Yokota T	BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer.	British journal of cancer	2011	79
22393095	673	Popovici V	Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer.	Journal of clinical oncology 	2012	47
22930283	673	Grisham RN	BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer.	Cancer	2013	27
22972589	673	Patel SP	Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.	Cancer	2013	28
23800934	673	Nishihara R	Aspirin use and risk of colorectal cancer according to BRAF mutation status.	JAMA	2013	48
23878352	673	Lochhead P	Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication.	Journal of the National Cancer Institute	2013	81
24737664	673	Yaeger R	BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer.	Cancer	2014	29
25918280	673	Fakih MG	Metastatic colorectal cancer: current state and future directions.	Journal of clinical oncology 	2015	33
26338525	673	Cremolini C	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.	The Lancet. Oncology	2015	39
26833129	1019	Bouillez A	Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas.	Cancer research	2016	14
20507599	1026	Baba Y	Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors.	Molecular cancer	2010	50
16799619	1029	Laurent-Puig P	Genetics of hepatocellular tumors.	Oncogene	2006	82
17065427	1029	Ogino S	CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations.	The Journal of molecular diagnostics 	2006	134
17088437	1029	Ikediobi ON	Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.	Molecular cancer therapeutics	2006	152
18922929	1029	Barault L	Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases.	Cancer research	2008	106
19825961	1029	Ogino S	Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype.	Clinical cancer research 	2009	92
21509761	1029	Ahn JB	DNA methylation predicts recurrence from resected stage III proximal colon cancer.	Cancer	2011	47
22067401	1029	Oberholzer PA	RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.	Journal of clinical oncology 	2012	79
22256804	1029	Su F	RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.	The New England journal of medicine	2012	200
22975375	1029	Navas C	EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma.	Cancer cell	2012	91
23470568	1029	Oshima M	Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.	Annals of surgery	2013	42
23907151	1029	Kanagal-Shamanna R	Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics.	Modern pathology 	2014	32
25536104	1029	Churi CR	Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.	PloS one	2014	40
26830752	1029	Kamisawa T	Pancreatic cancer.	Lancet	2016	47
27213815	1029	Dauch D	A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.	Nature medicine	2016	15
24764661	1045	Kim JH	Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer.	World journal of gastroenterology	2014	21
24548766	1048	Yang CY	Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes.	European journal of cancer	2014	58
19152896	1084	Khalid A	Pancreatic cyst fluid DNA analysis in evaluating pancreatic cysts: a report of the PANDA study.	Gastrointestinal endoscopy	2009	78
22586683	1399	Cheung HW	Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.	Cancer discovery	2011	45
21306997	1432	Sunaga N	Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.	Molecular cancer therapeutics	2011	54
15761464	1499	Bell DA	Origins and molecular pathology of ovarian cancer.	Modern pathology 	2005	100
21521850	1499	Morikawa T	Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer.	JAMA	2011	78
22071650	1499	Sequist LV	Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice.	Annals of oncology 	2011	92
22536370	1499	Lovly CM	Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.	PloS one	2012	49
22538770	1499	Santarpia L	Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.	Breast cancer research and treatment	2012	35
22653804	1499	McConechy MK	Use of mutation profiles to refine the classification of endometrial carcinomas.	The Journal of pathology	2012	45
22975805	1499	Seo JS	The transcriptional landscape and mutational profile of lung adenocarcinoma.	Genome research	2012	139
23325582	1499	Peeters M	Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.	Clinical cancer research 	2013	56
23636398	1499	Cancer Genome Atlas Research Network.	Integrated genomic characterization of endometrial carcinoma.	Nature	2013	552
23765252	1499	McConechy MK	Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.	Modern pathology 	2014	25
24436047	1499	Shern JF	Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.	Cancer discovery	2014	82
25720322	1499	Stelloo E	Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative.	Modern pathology 	2015	16
21828135	1788	Jankowska AM	Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.	Blood	2011	80
24142997	1788	Luthra R	Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring.	Haematologica	2014	30
20725992	1846	Gaedcke J	Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas.	Genes, chromosomes and cancer	2010	46
7559524	1950	Albanese C	Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions.	The Journal of biological chemistry	1995	207
18379349	1950	Beau-Faller M	MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.	Journal of thoracic oncology 	2008	60
25924068	1950	Drost J	Sequential cancer mutations in cultured human intestinal stem cells.	Nature	2015	71
15604253	1956	Kosaka T	Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.	Cancer research	2004	233
15737014	1956	Pao W	Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.	PLoS medicine	2005	871
15741570	1956	Shigematsu H	Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.	Journal of the National Cancer Institute	2005	439
15753357	1956	Shigematsu H	Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.	Cancer research	2005	142
15863375	1956	Moroni M	Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.	The Lancet. Oncology	2005	197
16231326	1956	Shigematsu H	Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers.	International journal of cancer	2006	139
16533793	1956	Tam IY	Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features.	Clinical cancer research 	2006	112
17020982	1956	Kosaka T	Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.	Clinical cancer research 	2006	131
17075123	1956	Hirsch FR	Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2006	145
17228019	1956	Jackman DM	Phase II clinical trial of chemotherapy-naive patients &amp;gt; or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer.	Journal of clinical oncology 	2007	82
17317677	1956	Hirsch FR	Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.	Annals of oncology 	2007	69
17504988	1956	Massarelli E	KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.	Clinical cancer research 	2007	154
17888036	1956	Mitsudomi T	Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer.	Cancer science	2007	121
18303429	1956	Marks JL	Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma.	Journal of thoracic oncology 	2008	71
18349398	1956	Miller VA	Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.	Journal of clinical oncology 	2008	66
18391747	1956	Motoi N	Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis.	The American journal of surgical pathology	2008	77
18626007	1956	Zhu CQ	Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.	Journal of clinical oncology 	2008	160
18794099	1956	Personeni N	Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study.	Clinical cancer research 	2008	51
18802721	1956	van Krieken JH	KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.	Virchows Archiv 	2008	73
19010912	1956	Pratilas CA	Genetic predictors of MEK dependence in non-small cell lung cancer.	Cancer research	2008	83
19096300	1956	Onozato R	Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.	Journal of thoracic oncology 	2009	61
19170230	1956	Wong DW	The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.	Cancer	2009	157
19188670	1956	Allegra CJ	American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.	Journal of clinical oncology 	2009	311
19234440	1956	Inamura K	EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.	Modern pathology 	2009	103
19447865	1956	Naumov GN	Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.	Clinical cancer research 	2009	55
19483740	1956	Linardou H	Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.	Nature reviews. Clinical oncology	2009	57
19536109	1956	Walther A	Genetic prognostic and predictive markers in colorectal cancer.	Nature reviews. Cancer	2009	170
19584155	1956	Schmid K	EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.	Clinical cancer research 	2009	66
19636327	1956	Normanno N	Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.	Nature reviews. Clinical oncology	2009	107
19667264	1956	Shaw AT	Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.	Journal of clinical oncology 	2009	383
19671843	1956	Jackman DM	Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.	Clinical cancer research 	2009	111
19680293	1956	Gazdar AF	Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.	Oncogene	2009	163
19738166	1956	Siena S	Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.	Journal of the National Cancer Institute	2009	144
19806185	1956	Sartore-Bianchi A	Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer.	PloS one	2009	85
19826477	1956	Soh J	Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells.	PloS one	2009	66
19884556	1956	Laurent-Puig P	Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.	Journal of clinical oncology 	2009	189
19942479	1956	Folprecht G	Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.	The Lancet. Oncology	2010	131
20038723	1956	Douillard JY	Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.	Journal of clinical oncology 	2010	141
20100958	1956	Khambata-Ford S	Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2010	63
20100961	1956	Bardelli A	Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.	Journal of clinical oncology 	2010	160
20103678	1956	Baldus SE	Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.	Clinical cancer research 	2010	109
20108024	1956	Suda K	Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation.	Cancer metastasis reviews	2010	44
20183914	1956	Takahashi T	Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.	Annals of surgical oncology	2010	80
20351699	1956	Harris TJ	The molecular pathology of cancer.	Nature reviews. Clinical oncology	2010	57
20399983	1956	Tol J	Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.	Clinical therapeutics	2010	50
20431034	1956	Tsiatis AC	Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications.	The Journal of molecular diagnostics 	2010	105
20624322	1956	Zhang X	Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.	Molecular cancer	2010	79
20824720	1956	da Cunha Santos G	Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.	Cancer	2010	42
20838621	1956	Punnoose EA	Molecular biomarker analyses using circulating tumor cells.	PloS one	2010	78
20855820	1956	Johnson FM	Phase II study of dasatinib in patients with advanced non-small-cell lung cancer.	Journal of clinical oncology 	2010	53
20855837	1956	Sun Y	Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.	Journal of clinical oncology 	2010	93
20864632	1956	Attolini CS	A mathematical framework to determine the temporal sequence of somatic genetic events in cancer.	Proceedings of the National Academy of Sciences of the United States of America	2010	47
20921461	1956	Roberts PJ	Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?	Journal of clinical oncology 	2010	77
20921462	1956	Peeters M	Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.	Journal of clinical oncology 	2010	181
20921465	1956	Douillard JY	Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.	Journal of clinical oncology 	2010	342
21062932	1956	Camidge DR	Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.	Clinical cancer research 	2010	75
21081655	1956	John T	The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer.	Clinical cancer research 	2011	38
21163703	1956	De Roock W	KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.	The Lancet. Oncology	2011	125
21200037	1956	Dahabreh IJ	Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer.	Annals of internal medicine	2011	47
21258250	1956	Ludovini V	Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.	Journal of thoracic oncology 	2011	44
21277552	1956	Pao W	New driver mutations in non-small-cell lung cancer.	The Lancet. Oncology	2011	244
21408138	1956	van Eijk R	Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR.	PloS one	2011	43
21483012	1956	Paik PK	Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.	Journal of clinical oncology 	2011	115
21502544	1956	Van Cutsem E	Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.	Journal of clinical oncology 	2011	350
21597390	1956	Suda K	Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.	Journal of thoracic oncology 	2011	69
21641636	1956	Maughan TS	Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.	Lancet	2011	199
21646616	1956	Price TJ	Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer.	Journal of clinical oncology 	2011	58
21720997	1956	Kim HR	Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.	Cancer	2012	33
21768463	1956	Sequist LV	Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.	Journal of clinical oncology 	2011	120
21969500	1956	Brugger W	Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2011	68
22025157	1956	Ramalingam SS	Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer.	Journal of clinical oncology 	2011	59
22135231	1956	Chaft JE	Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.	Molecular cancer therapeutics	2012	55
22140546	1956	Li C	Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers.	PloS one	2011	54
22178589	1956	Andersen JB	Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.	Gastroenterology	2012	76
22194472	1956	Ju YS	A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.	Genome research	2012	122
22209049	1956	O'Flaherty JD	Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer.	Lung cancer	2012	44
22228640	1956	Rekhtman N	Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.	Clinical cancer research 	2012	73
22235099	1956	Doebele RC	Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.	Clinical cancer research 	2012	213
22282022	1956	Doebele RC	Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer.	Cancer	2012	48
22315472	1956	Deng N	A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets.	Gut	2012	127
22317764	1956	Zhang Y	Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.	Clinical cancer research 	2012	46
22440336	1956	Scagliotti GV	Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.	Clinical lung cancer	2012	44
22464348	1956	Couraud S	Lung cancer in never smokers--a review.	European journal of cancer	2012	51
22590557	1956	Wilkerson MD	Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation.	PloS one	2012	45
22722830	1956	Misale S	Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.	Nature	2012	333
22722843	1956	Diaz LA Jr	The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.	Nature	2012	379
22768234	1956	An SJ	Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status.	PloS one	2012	50
22773810	1956	Ohashi K	Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.	Proceedings of the National Academy of Sciences of the United States of America	2012	121
22810899	1956	Johnson ML	Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.	Cancer	2013	32
23014527	1956	Dogan S	Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.	Clinical cancer research 	2012	74
23021375	1956	Berg M	EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy.	Discovery medicine	2012	32
23136247	1956	Gasch C	Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer.	Clinical chemistry	2013	55
23154553	1956	D'Angelo SP	Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.	Journal of thoracic oncology 	2012	36
23233388	1956	Mostert B	KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue.	International journal of cancer	2013	30
23242438	1956	Yoshizawa A	Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients.	Journal of thoracic oncology 	2013	67
23265711	1956	Licitra L	Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.	European journal of cancer	2013	27
23341890	1956	Li Y	Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer.	PloS one	2013	41
23362162	1956	Tuononen K	Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS.	Genes, chromosomes and cancer	2013	34
23391413	1956	Voss JS	Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions.	Human pathology	2013	38
23401440	1956	Roberts PJ	KRAS mutation: should we test for it, and does it matter?	Journal of clinical oncology 	2013	54
23404247	1956	Valtorta E	KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy.	International journal of cancer	2013	34
23470965	1956	Yu HA	Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.	Clinical cancer research 	2013	251
23486266	1956	Russell PA	Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.	Journal of thoracic oncology 	2013	29
23553849	1956	Socinski MA	A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.	Clinical cancer research 	2013	70
23723294	1956	Dearden S	Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap).	Annals of oncology 	2013	58
23729361	1956	Gainor JF	ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.	Clinical cancer research 	2013	85
23814043	1956	Gainor JF	Novel targets in non-small cell lung cancer: ROS1 and RET fusions.	The oncologist	2013	35
23833300	1956	Cardarella S	Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.	Clinical cancer research 	2013	34
23883922	1956	Garassino MC	Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.	The Lancet. Oncology	2013	116
23891509	1956	Tsuta K	The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations.	Lung cancer	2013	35
23931927	1956	Gridelli C	ALK inhibitors in the treatment of advanced NSCLC.	Cancer treatment reviews	2014	34
24098024	1956	Pichler M	miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor.	Journal of clinical pathology	2014	26
24236184	1956	Scarpa A	Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel.	PloS one	2013	28
24429876	1956	Oxnard GR	Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA.	Clinical cancer research 	2014	111
24501009	1956	Reckamp KL	A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.	Cancer	2014	23
24513263	1956	Vanderlaan PA	Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer.	Lung cancer	2014	20
24666267	1956	Therkildsen C	The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.	Acta oncologica	2014	56
24685132	1956	Sun C	Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.	Cell reports	2014	43
24687833	1956	Schwartzberg LS	PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.	Journal of clinical oncology 	2014	99
24743704	1956	Li S	Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.	British journal of cancer	2014	25
24846037	1956	Kris MG	Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.	JAMA	2014	182
24857124	1956	Gerber DE	Management and future directions in non-small cell lung cancer with known activating mutations.	American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting	2014	23
24919569	1956	Van Cutsem E	Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.	Clinical cancer research 	2014	22
24939055	1956	Qu Y	Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.	Journal of experimental and clinical cancer research 	2014	22
25013125	1956	Couraud S	Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002.	Clinical cancer research 	2014	40
25115304	1956	Sorich MJ	Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.	Annals of oncology 	2015	68
25164765	1956	Brannon AR	Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions.	Genome biology	2014	54
25248381	1956	Laurent-Puig P	Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy.	Clinical cancer research 	2015	30
25345567	1956	Hagemann IS	Clinical next-generation sequencing in patients with non-small cell lung cancer.	Cancer	2015	29
25444907	1956	Hao C	Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer.	Cancer letters	2015	18
25567908	1956	Drilon A	Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.	Clinical cancer research 	2015	30
25593032	1956	Linnekamp JF	Colorectal cancer heterogeneity and targeted therapy: a case for molecular disease subtypes.	Cancer research	2015	21
25605843	1956	Van Cutsem E	Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.	Journal of clinical oncology 	2015	74
25623215	1956	Arena S	Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.	Clinical cancer research 	2015	24
25628445	1956	Morelli MP	Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment.	Annals of oncology 	2015	22
25629635	1956	Wu C	High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules.	Journal of thoracic oncology 	2015	16
25639985	1956	Mao C	Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases.	Scientific reports	2015	19
25667274	1956	Lopez-Chavez A	Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.	Journal of clinical oncology 	2015	33
25673644	1956	Ahronian LG	Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.	Cancer discovery	2015	46
25738220	1956	Sholl LM	Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.	Journal of thoracic oncology 	2015	37
25870145	1956	Eberlein CA	Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.	Cancer research	2015	30
25956936	1956	Rizzo S	CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer.	European radiology	2016	12
26024796	1956	Cooper WA	PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.	Lung cancer	2015	29
26030179	1956	Siravegna G	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.	Nature medicine	2015	58
26243863	1956	Kavuri SM	HER2 activating mutations are targets for colorectal cancer treatment.	Cancer discovery	2015	18
26318427	1956	Bronte G	New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?	Oncotarget	2015	16
26358176	1956	Dietel M	A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.	Cancer gene therapy	2015	25
26438111	1956	Allegra CJ	Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015.	Journal of clinical oncology 	2016	31
26460303	1956	Kopetz S	Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.	Journal of clinical oncology 	2015	41
26477306	1956	Schabath MB	Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma.	Oncogene	2016	11
26525104	1956	Best MG	RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics.	Cancer cell	2015	34
26582655	1956	Xu S	Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients.	Cancer letters	2016	12
26625312	1956	Pécuchet N	Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer.	Oncotarget	2017	5
26644315	1956	Russo M	Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.	Cancer discovery	2016	23
26690310	1956	Richman SD	HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.	The Journal of pathology	2016	11
26729443	1956	Awad MM	MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.	Journal of clinical oncology 	2016	33
26735353	1956	Bournet B	Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.	European journal of cancer	2016	16
26777916	1956	Barlesi F	Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).	Lancet	2016	43
26799287	1956	Del Re M	Contribution of KRAS mutations and c.2369C &amp;gt; T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA.	Oncotarget	2017	9
26844548	1956	Hedner C	Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma.	PloS one	2016	11
26942675	1956	Li X	Mitochondria-Translocated PGK1 Functions as a Protein Kinase to Coordinate Glycolysis and the TCA Cycle in Tumorigenesis.	Molecular cell	2016	14
27060149	1956	Lai Z	VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research.	Nucleic acids research	2016	12
27688480	1956	Yip SS	Associations Between Somatic Mutations and Metabolic Imaging Phenotypes in Non-Small Cell Lung Cancer.	Journal of nuclear medicine 	2017	7
23542178	1978	Ducker GS	Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.	Oncogene	2014	26
24390348	1999	Ojesina AI	Landscape of genomic alterations in cervical carcinomas.	Nature	2014	113
22761469	2064	Arcila ME	Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.	Clinical cancer research 	2012	53
22899400	2064	Anglesio MS	Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.	The Journal of pathology	2013	31
23589555	2064	Sleijfer S	Designing transformative clinical trials in the cancer genome era.	Journal of clinical oncology 	2013	35
23610105	2064	Mazières J	Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.	Journal of clinical oncology 	2013	82
25896973	2064	Chantrill LA	Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial.	Clinical cancer research 	2015	25
7491495	2099	Kato S	Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase.	Science	1995	322
9524123	2099	Migliaccio A	Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor.	The EMBO journal	1998	119
23026827	2260	Drilon A	Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy.	The Lancet. Oncology	2012	47
21072204	2261	Kompier LC	FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.	PloS one	2010	63
25608663	2263	Sia D	Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma.	Nature communications	2015	29
25253770	2322	Irving J	Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition.	Blood	2014	39
20664172	2475	Di Nicolantonio F	Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.	The Journal of clinical investigation	2010	110
21998291	2475	Wallin JJ	GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.	Molecular cancer therapeutics	2011	64
23012248	2475	Acquaviva J	Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.	Molecular cancer therapeutics	2012	32
24430184	2475	Li H	Inactivation of SAG/RBX2 E3 ubiquitin ligase suppresses KrasG12D-driven lung tumorigenesis.	The Journal of clinical investigation	2014	21
26293922	2475	Liu P	PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex.	Cancer discovery	2015	30
21775669	2778	Wu J	Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development.	Science translational medicine	2011	146
25305506	2956	Sinicrope FA	Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.	Gastroenterology	2015	42
15572290	3251	DeMarini DM	Genotoxicity of tobacco smoke and tobacco smoke condensate: a review.	Mutation research	2004	95
15188009	3265	Bamford S	The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website.	British journal of cancer	2004	351
16170316	3265	Aoki Y	Germline mutations in HRAS proto-oncogene cause Costello syndrome.	Nature genetics	2005	149
22004085	3265	Baines AT	Inhibition of Ras for cancer treatment: the search continues.	Future medicinal chemistry	2011	98
23264394	3265	Agrawal N	Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS.	The Journal of clinical endocrinology and metabolism	2013	34
23640968	3265	Crona J	Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing.	The Journal of clinical endocrinology and metabolism	2013	25
24695311	3265	Cleary AS	Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers.	Nature	2014	71
25086355	3265	Lee TH	Oncogenic ras-driven cancer cell vesiculation leads to emission of double-stranded DNA capable of interacting with target cells.	Biochemical and biophysical research communications	2014	27
26985062	3265	Hobbs GA	RAS isoforms and mutations in cancer at a glance.	Journal of cell science	2016	17
22180306	3417	Borger DR	Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.	The oncologist	2012	126
22319590	3717	Looyenga BD	STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma.	PloS one	2012	35
23382536	3717	Hiatt JB	Single molecule molecular inversion probes for targeted, high-accuracy detection of low-frequency variation.	Genome research	2013	68
22327624	3799	Kohno T	KIF5B-RET fusions in lung adenocarcinoma.	Nature medicine	2012	170
9727023	3845	Yan J	Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase.	The Journal of biological chemistry	1998	102
12644542	3845	Singer G	Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.	Journal of the National Cancer Institute	2003	164
15608639	3845	Sweet-Cordero A	An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis.	Nature genetics	2005	159
15998951	3845	Ince WL	Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.	Journal of the National Cancer Institute	2005	69
16474405	3845	Schubbert S	Germline KRAS mutations cause Noonan syndrome.	Nature genetics	2006	154
16618717	3845	Lièvre A	KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.	Cancer research	2006	491
16931950	3845	Brune K	Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer.	The American journal of surgical pathology	2006	69
17184525	3845	Krypuy M	High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer.	BMC cancer	2006	78
17375050	3845	Di Fiore F	Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy.	British journal of cancer	2007	192
17998284	3845	De Roock W	KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.	Annals of oncology 	2008	206
18202412	3845	Lièvre A	KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.	Journal of clinical oncology 	2008	336
18224685	3845	Barault L	Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers.	International journal of cancer	2008	84
18316791	3845	Amado RG	Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.	Journal of clinical oncology 	2008	728
18669866	3845	Perrone F	PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients.	Annals of oncology 	2009	112
18794081	3845	Riely GJ	Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.	Clinical cancer research 	2008	131
19001320	3845	Di Nicolantonio F	Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.	Journal of clinical oncology 	2008	416
19056857	3845	Santini D	High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.	The oncologist	2008	57
19114683	3845	Bokemeyer C	Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.	Journal of clinical oncology 	2009	369
19124802	3845	Jimeno A	KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection.	Journal of clinical oncology 	2009	58
19196673	3845	Tol J	Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.	The New England journal of medicine	2009	287
19237633	3845	Ogino S	PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer.	Journal of clinical oncology 	2009	111
19339720	3845	Van Cutsem E	Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.	The New England journal of medicine	2009	786
19349489	3845	Riely GJ	KRAS mutations in non-small cell lung cancer.	Proceedings of the American Thoracic Society	2009	142
19398573	3845	Loupakis F	PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.	Journal of clinical oncology 	2009	123
19401449	3845	Wee S	PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.	Cancer research	2009	116
19490892	3845	Scholl C	Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.	Cell	2009	189
19603018	3845	Loupakis F	KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.	British journal of cancer	2009	136
19603024	3845	Souglakos J	Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.	British journal of cancer	2009	76
19661383	3845	Yun J	Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells.	Science	2009	210
19686742	3845	Nosho K	A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers.	Gastroenterology	2009	53
19738126	3845	Jacobs B	Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.	Journal of clinical oncology 	2009	84
19884549	3845	Richman SD	KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.	Journal of clinical oncology 	2009	146
19908233	3845	Zlobec I	Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.	International journal of cancer	2010	58
19934290	3845	Ogino S	KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.	Clinical cancer research 	2009	62
20008640	3845	Roth AD	Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.	Journal of clinical oncology 	2010	282
20022659	3845	Mao C	KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies.	Lung cancer	2010	74
20102720	3845	Goel A	Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency.	Gastroenterology	2010	42
20413299	3845	Tol J	Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.	European journal of cancer	2010	61
20501503	3845	Fariña-Sarasqueta A	The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients.	Annals of oncology 	2010	72
20505728	3845	Lee W	The mutation spectrum revealed by paired genome sequences from a lung cancer patient.	Nature	2010	197
20512148	3845	Lauth M	DYRK1B-dependent autocrine-to-paracrine shift of Hedgehog signaling by mutant RAS.	Nature structural and molecular biology	2010	48
20570890	3845	Janakiraman M	Genomic and biological characterization of exon 4 KRAS mutations in human cancer.	Cancer research	2010	92
20603437	3845	Zhang W	A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy.	Annals of oncology 	2011	37
20619739	3845	De Roock W	Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.	The Lancet. Oncology	2010	475
20699365	3845	Halilovic E	PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.	Cancer research	2010	49
20736745	3845	Irahara N	NRAS mutations are rare in colorectal cancer.	Diagnostic molecular pathology 	2010	43
20841479	3845	Cepero V	MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors.	Cancer research	2010	46
20927778	3845	Nosho K	Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review.	The Journal of pathology	2010	104
20978259	3845	De Roock W	Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.	JAMA	2010	186
21228335	3845	Bokemeyer C	Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.	Annals of oncology 	2011	163
21239505	3845	Tie J	KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer.	Clinical cancer research 	2011	47
21305640	3845	Vaughn CP	Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer.	Genes, chromosomes and cancer	2011	59
21364579	3845	Knijn N	KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients.	British journal of cancer	2011	63
21383284	3845	Hutchins G	Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.	Journal of clinical oncology 	2011	125
21435948	3845	Paranjape T	A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis.	The Lancet. Oncology	2011	44
21519026	3845	Bekaii-Saab T	Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers.	Journal of clinical oncology 	2011	60
21543894	3845	Chan E	MicroRNA signatures differentiate melanoma subtypes.	Cell cycle	2011	35
21594292	3845	Pekin D	Quantitative and sensitive detection of rare mutations using droplet-based microfluidics.	Lab on a chip	2011	61
21632860	3845	Molinari F	Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.	Clinical cancer research 	2011	56
21943101	3845	Makrodouli E	BRAF and RAS oncogenes regulate Rho GTPase pathways to mediate migration and invasion properties in human colon cancer cells: a comparative study.	Molecular cancer	2011	36
21985784	3845	Ebi H	Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.	The Journal of clinical investigation	2011	63
22228631	3845	Spindler KL	Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.	Clinical cancer research 	2012	44
22247021	3845	Ihle NT	Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.	Journal of the National Cancer Institute	2012	83
22266220	3845	O'Dell MR	Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma.	Cancer research	2012	33
22282465	3845	Miranda C	KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors.	Clinical cancer research 	2012	38
22314188	3845	Pai RK	BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.	The American journal of surgical pathology	2012	35
22341439	3845	Singh A	TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers.	Cell	2012	84
22446022	3845	Bokemeyer C	Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials.	European journal of cancer	2012	123
22473155	3845	Tveit KM	Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.	Journal of clinical oncology 	2012	106
22474202	3845	Alberts SR	Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial.	JAMA	2012	89
22481281	3845	Chang DT	Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features.	Modern pathology 	2012	33
22613949	3845	Steckel M	Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.	Cell research	2012	45
22665543	3845	Vakiani E	Comparative genomic analysis of primary versus metastatic colorectal carcinomas.	Journal of clinical oncology 	2012	67
22734028	3845	Tejpar S	Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.	Journal of clinical oncology 	2012	98
22753589	3845	Imamura Y	Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers.	Clinical cancer research 	2012	62
22798500	3845	Tian S	A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.	Gut	2013	26
22898602	3845	Ward AF	Targeting oncogenic Ras signaling in hematologic malignancies.	Blood	2012	50
23122493	3845	Karachaliou N	KRAS mutations in lung cancer.	Clinical lung cancer	2013	31
23182985	3845	Peeters M	Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.	Journal of clinical oncology 	2013	63
23200175	3845	Jänne PA	Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.	The Lancet. Oncology	2013	153
23293113	3845	Tougeron D	Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer.	Annals of oncology 	2013	29
23295441	3845	Sia D	Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.	Gastroenterology	2013	61
23334325	3845	Huang H	Oncogenic K-Ras requires activation for enhanced activity.	Oncogene	2014	31
23348904	3845	Rosty C	Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features.	Modern pathology 	2013	47
23374602	3845	Pentheroudakis G	Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.	BMC cancer	2013	33
23419522	3845	Fabbri F	Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs.	Cancer letters	2013	47
23471846	3845	Heitzer E	Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing.	Cancer research	2013	122
23511557	3845	Phipps AI	KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers.	British journal of cancer	2013	40
23614898	3845	Morris EJ	Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.	Cancer discovery	2013	94
23630215	3845	Shepherd FA	Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.	Journal of clinical oncology 	2013	45
23660947	3845	Eklöf V	The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer.	British journal of cancer	2013	38
23725851	3845	Seymour MT	Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.	The Lancet. Oncology	2013	65
23792451	3845	Ogino S	Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.	Oncogene	2014	38
23912084	3845	Murphy SJ	Genetic alterations associated with progression from pancreatic intraepithelial neoplasia to invasive pancreatic tumor.	Gastroenterology	2013	33
23943799	3845	Licciulli S	Notch1 is required for Kras-induced lung adenocarcinoma and controls tumor cell survival via p53.	Cancer research	2013	27
24018645	3845	Vauthey JN	RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.	Annals of surgery	2013	29
24024839	3845	Douillard JY	Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.	The New England journal of medicine	2013	383
24042191	3845	Mouradov D	Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations.	The American journal of gastroenterology	2013	27
24043732	3845	Piessevaux H	Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab.	Journal of clinical oncology 	2013	28
24297898	3845	Zorde Khvalevsky E	Mutant KRAS is a druggable target for pancreatic cancer.	Proceedings of the National Academy of Sciences of the United States of America	2013	37
24385213	3845	Tahara T	Fusobacterium in colonic flora and molecular features of colorectal carcinoma.	Cancer research	2014	46
24398677	3845	Kahlert C	Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer.	The Journal of biological chemistry	2014	94
24525237	3845	Grabocka E	Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response.	Cancer cell	2014	31
24645800	3845	Imperiale TF	Multitarget stool DNA testing for colorectal-cancer screening.	The New England journal of medicine	2014	144
24658074	3845	Thierry AR	Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA.	Nature medicine	2014	70
24681997	3845	Thege FI	Microfluidic immunocapture of circulating pancreatic cells using parallel EpCAM and MUC1 capture: characterization, optimization and downstream analysis.	Lab on a chip	2014	23
24687927	3845	Yoon HH	KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).	Clinical cancer research 	2014	22
25051912	3845	Zoratto F	Focus on genetic and epigenetic events of colorectal cancer pathogenesis: implications for molecular diagnosis.	Tumour biology 	2014	35
25280443	3845	Phipps AI	Association between molecular subtypes of colorectal cancer and patient survival.	Gastroenterology	2015	75
25361982	3845	Klingbiel D	Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial.	Annals of oncology 	2015	20
25632066	3845	Chen JS	A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer.	Annals of oncology 	2015	17
25706875	3845	Matano M	Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids.	Nature medicine	2015	74
25722381	3845	Blumenschein GR Jr	A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.	Annals of oncology 	2015	18
25877855	3845	Tabernero J	Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.	The Lancet. Oncology	2015	69
25937522	3845	Bokemeyer C	FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer.	European journal of cancer	2015	24
25961927	3845	Garcia PL	The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models.	Oncogene	2016	23
26084335	3845	Kim KT	Single-cell mRNA sequencing identifies subclonal heterogeneity in anti-cancer drug responses of lung adenocarcinoma cells.	Genome biology	2015	32
26085511	3845	Frenel JS	Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration.	Clinical cancer research 	2015	31
26216840	3845	Carethers JM	Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer.	Gastroenterology	2015	32
26608120	3845	Johnson DB	Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.	European journal of cancer	2015	18
26627737	3845	Hart T	High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.	Cell	2015	78
26739882	3845	Patricelli MP	Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.	Cancer discovery	2016	22
16174854	4255	Shen L	MGMT promoter methylation and field defect in sporadic colorectal cancer.	Journal of the National Cancer Institute	2005	149
21880806	4893	Nikiforov YE	Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples.	The Journal of clinical endocrinology and metabolism	2011	95
22048237	4893	Kirkwood JM	Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.	Clinical cancer research 	2012	76
23414587	4893	Ascierto PA	MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.	The Lancet. Oncology	2013	129
23515407	4893	Ohashi K	Characteristics of lung cancers harboring NRAS mutations.	Clinical cancer research 	2013	30
17314276	5290	Hollestelle A	Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.	Molecular cancer research 	2007	106
18757405	5290	Yamamoto H	PIK3CA mutations and copy number gains in human lung cancers.	Cancer research	2008	140
19223544	5290	Sartore-Bianchi A	PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.	Cancer research	2009	197
19261849	5290	Salvesen HB	Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation.	Proceedings of the National Academy of Sciences of the United States of America	2009	83
19349352	5290	Kuo KT	Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma.	The American journal of pathology	2009	89
21266528	5290	Rudd ML	A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas.	Clinical cancer research 	2011	71
21829508	5290	Janku F	PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.	PloS one	2011	60
22039088	5290	Mao C	PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.	Annals of oncology 	2012	51
22188813	5290	Maira SM	Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.	Molecular cancer therapeutics	2012	118
22271473	5290	Janku F	PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.	Journal of clinical oncology 	2012	145
22285706	5290	Sood A	PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.	Clinical colorectal cancer	2012	33
22357840	5290	Liao X	Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review.	Clinical cancer research 	2012	88
23066039	5290	Janku F	PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.	Cancer research	2013	76
23094721	5290	Liao X	Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.	The New England journal of medicine	2012	204
23248156	5290	Janku F	PIK3CA mutations in advanced cancers: characteristics and outcomes.	Oncotarget	2012	30
23739063	5290	Loi S	Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.	Journal of the National Cancer Institute	2013	34
23785428	5290	Rosty C	PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival.	PloS one	2013	31
24533074	5290	Wang L	PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.	PloS one	2014	25
20826764	5518	Jones S	Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.	Science	2010	317
26352686	5594	Tiacci E	Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.	The New England journal of medicine	2015	19
17940504	5728	Frattini M	PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients.	British journal of cancer	2007	135
17143285	5781	Roberts AE	Germline gain-of-function mutations in SOS1 cause Noonan syndrome.	Nature genetics	2007	125
24248188	5979	Jung CK	The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations.	The Journal of clinical endocrinology and metabolism	2014	49
17143282	6654	Tartaglia M	Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome.	Nature genetics	2007	124
24942275	10156	Ciardiello F	Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial.	Annals of oncology 	2014	23
25851630	10156	Normanno N	Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.	Annals of oncology 	2015	23
23104212	10178	Roth AD	Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.	Journal of the National Cancer Institute	2012	45
24803537	10413	Zhang W	Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma.	Science signaling	2014	58
25388162	10413	Lee KW	Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients.	Clinical cancer research 	2015	18
26121086	10413	Schramm A	Mutational dynamics between primary and relapse neuroblastomas.	Nature genetics	2015	37
26950094	10413	Bonilla X	Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma.	Nature genetics	2016	19
24296758	10568	Aisner DL	ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.	Molecular cancer research 	2014	30
27338794	10818	Manchado E	A combinatorial strategy for treating KRAS-mutant lung cancer.	Nature	2016	23
12438234	22882	Yuen ST	Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.	Cancer research	2002	95
12692057	22882	Tannapfel A	Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma.	Gut	2003	92
18372904	22882	Haigis KM	Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon.	Nature genetics	2008	193
18390968	22882	Adjei AA	Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.	Journal of clinical oncology 	2008	161
24178622	22882	Jain N	Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.	Clinical cancer research 	2014	27
25324352	22882	Hyman DM	Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders.	Cancer discovery	2015	27
25878360	22882	McCormick F	KRAS as a Therapeutic Target.	Clinical cancer research 	2015	29
24893629	23463	Vasan N	A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer.	Clinical cancer research 	2014	22
27196573	29126	Masugi Y	Tumour CD274 (PD-L1) expression and T cells in colorectal cancer.	Gut	2017	8
20644105	54790	Kohlmann A	Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.	Journal of clinical oncology 	2010	65
22116554	54790	Weissmann S	Landscape of TET2 mutations in acute myeloid leukemia.	Leukemia	2012	41
22810696	139285	Cancer Genome Atlas Network.	Comprehensive molecular characterization of human colon and rectal cancer.	Nature	2012	1543
20880116	171023	Gelsi-Boyer V	ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia.	British journal of haematology	2010	46
23690417	171023	Itzykson R	Prognostic score including gene mutations in chronic myelomonocytic leukemia.	Journal of clinical oncology 	2013	70
23958953	171023	Schwaab J	Comprehensive mutational profiling in advanced systemic mastocytosis.	Blood	2013	28
22343534	100271849	Lohr JG	Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing.	Proceedings of the National Academy of Sciences of the United States of America	2012	240
